Bcl-2 expresszió vizsgálata hererákokban, összefüggésben a tumorprogresszióval.

Translated title of the contribution: Bcl-2 expression in testicular cancer in relation to tumor progression

H. Eid, M. Gulyás, A. Mágori, L. Géczi, I. Bodrogi, E. Institioris, M. Bak

Research output: Contribution to journalReview article


Bcl-2 expression has been studied extensively in a variety of human tumors. However, there are lack of clinical data in regard to its expression in germ cell testicular tumors (GCTTs). In this study we screened bcl-2 expression in 70 patient with GCTTs using the immunohistochemistry (IHC) and streptavidin biotin alkaline phosphatase method. Furthermore, we correlated this expression with metastatic behaviour and clinical stage. Overall, 41 (58%) carcinomas stained with anti-bcl-2 (DAKO-124) monoclonal antibody, By histologic type, these lesions included 11 (42.3%) of 26 seminomas (S) and 30 (68.18%) of 44 non seminomatous germ cell testicular tumors (NSGCT). The incidence of bcl-2 immunostaining was higher (P = 0.05, two-tailed, Fisher's test) in NSGCT than in seminomas. Bcl-2 expression was higher in tumors from metastatic patients than in tumors from metastatic-free patient (p = 0). There was a significant difference between the three stages of disease as to the expression of bcl-2 (chi 2 = 0). High level of bcl-2 was clearly dominant in tumors of advanced stages. The present finding revealed that bcl-2 expression occurs in GCTTs. Further, they suggested that bcl-2 is associated with a more progressed malignant phenotype in these tumors.

Translated title of the contributionBcl-2 expression in testicular cancer in relation to tumor progression
Original languageHungarian
Pages (from-to)2137-2140
Number of pages4
JournalOrvosi hetilap
Issue number36
Publication statusPublished - Sep 6 1998

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Bcl-2 expression in testicular cancer in relation to tumor progression'. Together they form a unique fingerprint.

  • Cite this